Showing 2,821 - 2,840 results of 2,897 for search '"stem cells"', query time: 0.09s Refine Results
  1. 2821

    Radioprotective Effects of Vitis vinifera L. Seed against Radiation-Induced Short-Term Memory Loss in Young Adult Wistar Rats by Ayomide Abe, Fatai Balogun, Olugbenga Ayannuga

    Published 2024-10-01
    “…While dose fractionation, intensity-modulated radiotherapy, and neural stem cell transplantation have demonstrated limited effectiveness, natural plant antioxidants offer a promising alternative. …”
    Get full text
    Article
  2. 2822

    Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

    Published 2025-02-01
    “…Patients with DLBCL (vs HGBCL), complete response before infusion, prior autologous or allogeneic haematopoietic stem cell transplant and lactate dehydrogenase (LDH) within normal limits experienced more favourable efficacy outcomes, and those with Eastern Cooperative Oncology Group performance status of ≥2, ≥3 prior lines of therapy, elevated LDH and fludarabine-based lymphodepleting chemotherapy experienced less favourable safety outcomes.Conclusions This real-world study of tisagenlecleucel for patients with R/R DLBCL/HGBCL shows consistent efficacy and better safety outcomes than the pivotal trial. …”
    Get full text
    Article
  3. 2823

    Occupational adjustments and work ability of young adult cancer survivors: results from the AYA-Leipzig study by Hannah Brock, Katharina Schröter, Michael Friedrich, Annekathrin Sender, Diana Richter, Anja Mehnert-Theuerkauf, Kristina Geue, Katja Leuteritz

    Published 2024-12-01
    “…Younger age (< 30) and stem cell transplant were associated with a lower benefit of support from colleagues (R2 = 0.077). …”
    Get full text
    Article
  4. 2824

    Variational Approaches for Drug-Disease-Gene Links in Periodontal Inflammation by Pradeep Kumar Yadalam, Prabhu Manickam Natarajan, Musab Hamed Saeed, Carlos M. Ardila

    Published 2025-02-01
    “…Introduction and Objectives: Oral diseases, including gingivitis and periodontitis, are linked to the Wnt signaling pathway, vital for bone metabolism, cementum homeostasis, and mesenchymal stem cell differentiation. Advances in generative AI techniques, such as variational autoencoders (VAEs) and quantum variational classifiers (QVCs), offer promising tools for predicting gene associations between drugs and diseases. …”
    Get full text
    Article
  5. 2825

    Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

    Published 2025-02-01
    “…Elevated expression of TFF3 promoted the oncogenicity of ER+HER2+ MC cells, including enhanced cell proliferation, survival, anchorage-independent growth, 3D growth, cancer stem cell-like (CSC-like) phenotype, migration, invasion, and xenograft growth. …”
    Get full text
    Article
  6. 2826

    Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML by Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer

    Published 2025-01-01
    “…Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non–VEN-containing salvage therapy according to their treating physician’s choice (TPC). …”
    Get full text
    Article
  7. 2827

    A novel strategy for the protective effect of ginsenoside Rg1 against ovarian reserve decline by the PINK1 pathway by Pengdi Yang, Meiling Fan, Ying Chen, Dan Yang, Lu Zhai, Baoyu Fu, Lili Zhang, Yanping Wang, Rui Ma, Liwei Sun

    Published 2025-12-01
    “…Protein expression levels in the PINK1/Parkin pathway were assessed, and molecular docking and PINK1 mutant analyses were conducted to identify potential targets.Results Ginsenoside Rg1 significantly mitigated ovarian reserve decline, enhancing offspring quantity and quality, increasing the levels of ecdysteroids, preventing ovarian atrophy, and elevating germline stem cell numbers in aged Drosophila. Ginsenoside Rg1 improved superoxide dismutase, catalase activity, and gene expression while reducing reactive oxygen species levels. …”
    Get full text
    Article
  8. 2828

    Single‐cell landscape of the intrahepatic ecosystem in alcohol‐related liver disease by Xiaofang Zhao, Senyan Wang, Qi Liu, Wenjuan Wei, Xiaoyan Sun, Hao Song, Jing Xu, Shuijun Zhang, Hongyang Wang, Jing Fu

    Published 2025-01-01
    “…The ALB+KRT7+ epithelial cells were demonstrated to have stem cell properties and malignant transformation potentials. …”
    Get full text
    Article
  9. 2829
  10. 2830

    The potential role of differentially expressed tRNA-derived fragments in high glucose-induced podocytes by Zhenxing Zhang, Yunyang Qiao, Jialing Ji, Chan Huang, Huimin Shi, Weihua Gan, Aiqing Zhang

    Published 2024-12-01
    “…KEGG pathway analysis revealed that tRFs may be involved in signaling pathways related to growth hormones, phospholipase D, the regulation of stem cell pluripotency, and T-/B-cell receptors. Overexpression of tRF-1:24, one of the most differentially expressed tRFs, attenuated podocyte injury induced by HG. …”
    Get full text
    Article
  11. 2831

    Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin

    Published 2022-08-01
    “…Three-month inpatient IRs were 0.6, 0.7, and 1.4 days in the CML-CP On Treatment, CML-CP Post-Discontinuation, and CML-AP/BC cohort, respectively, with mean costs of $5892 per day. Mean hematopoietic stem cell transplantation cost was $352&#8239;333; mean 3-month terminal care cost was $107 013. …”
    Get full text
    Article
  12. 2832

    Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV s... by Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas

    Published 2025-01-01
    “…Previous studies reported higher rates of post– hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. …”
    Get full text
    Article
  13. 2833
  14. 2834
  15. 2835
  16. 2836
  17. 2837
  18. 2838
  19. 2839
  20. 2840